Impaired activation of lesional CD8+ T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis
Post Kala-azar dermal leishmaniasis (PKDL), caused by Leishmania donovani is the dermal sequel of Visceral Leishmaniasis and importantly, is the proposed disease reservoir. The survival of Leishmania parasites within monocytes/macrophages hinges on its ability to effectively nullify immune activatio...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2019-01, Vol.9 (1), p.762-762, Article 762 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Post Kala-azar dermal leishmaniasis (PKDL), caused by
Leishmania donovani
is the dermal sequel of Visceral Leishmaniasis and importantly, is the proposed disease reservoir. The survival of
Leishmania
parasites within monocytes/macrophages hinges on its ability to effectively nullify immune activation mechanisms. Thus, delineating the disease-promoting immune mechanisms can facilitate development of immunotherapeutic strategies. Accordingly, in the absence of an animal model, this study aimed to delineate the status of CD8
+
T-cells in patients with PKDL. At disease presentation, the absence of CD4
+
T-cells at lesional sites was concomitant with an overwhelming infiltration of CD8
+
T-cells that demonstrated an absence of Perforin, Granzyme and Zap-70, along with an enhanced expression of Programmed Death-1 (PD-1) and the skin-homing CCL17. Additionally, the lesional CCR4
+
CD8
+
population was associated with an enhanced expression of IL-10 and IL-5. In circulation, the enhanced CD8
+
CCR4
+
T-cell population and raised levels of CCL17/22 was associated with an increased frequency of PD-1, while CD127 was decreased. Taken together, in PKDL, the enhanced plasma and lesional CCL17 accounted for the dermal homing of CD8
+
CCR4
+
T-cells, that along with a concomitant upregulation of PD-1 and IL-10 mediated immune inactivation, emphasizing the need for designing immunotherapies capable of reinvigorating T-cell potency. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-018-37144-y |